Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 2
2021 8
2022 4
2023 4
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ruijin hong[Author] (36 results)?
CAR T-cell therapies in China: rapid evolution and a bright future.
Hu Y, Feng J, Gu T, Wang L, Wang Y, Zhou L, Hong R, Tan Su Yin E, Zhang M, Lu P, Huang H. Hu Y, et al. Among authors: hong r. Lancet Haematol. 2022 Dec;9(12):e930-e941. doi: 10.1016/S2352-3026(22)00291-5. Lancet Haematol. 2022. PMID: 36455608 Review.
CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.
Hu Y, Li J, Ni F, Yang Z, Gui X, Bao Z, Zhao H, Wei G, Wang Y, Zhang M, Hong R, Wang L, Wu W, Mohty M, Nagler A, Chang AH, van den Brink MRM, Li MD, Huang H. Hu Y, et al. Among authors: hong r. Nat Commun. 2022 Sep 9;13(1):5313. doi: 10.1038/s41467-022-32960-3. Nat Commun. 2022. PMID: 36085303 Free PMC article. Clinical Trial.
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, Zhao H, Chen R, Zu C, Gu T, Xiao P, Hong R, Feng J, Fu S, Kong D, Xu H, Cui J, Huang S, Liang B, Yuan X, Cui Q, Guo H, Yu Y, Feng Y, Jin C, Ren J, Chang AH, Wang D, Huang H. Hu Y, et al. Among authors: hong r. N Engl J Med. 2024 Apr 25;390(16):1467-1480. doi: 10.1056/NEJMoa2313812. N Engl J Med. 2024. PMID: 38657244
Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study.
Hu Y, Zu C, Zhang M, Wei G, Li W, Fu S, Hong R, Zhou L, Wu W, Cui J, Wang D, Du B, Liu M, Zhang J, Huang H. Hu Y, et al. Among authors: hong r. EClinicalMedicine. 2023 May 18;60:102010. doi: 10.1016/j.eclinm.2023.102010. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37251628 Free PMC article.
Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, Yan X, Zhang Q, Zhang M, Wang L, Hong R, Chang AH, Yu J, Fu S, Kong D, Li L, Wang Y, Li Z, Jiang H, Huang J, Liu Z, Su N, Wei G, Hu Y, Huang H. Zhou L, et al. Among authors: hong r. Br J Haematol. 2023 Aug;202(3):517-524. doi: 10.1111/bjh.18873. Epub 2023 May 16. Br J Haematol. 2023. PMID: 37192741
22 results